Cogstate Ltd (ASX: CGS) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Cogstate Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $196.40 million
P/E Ratio 24.60
Dividend Yield 0.00%
Shares Outstanding 170.78 million
Earnings per share 0.031
Dividend per share N/A
Year To Date Return -19.03%
Earnings Yield 4.06%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Cogstate Ltd (ASX: CGS)
    Latest News

    young boys open mouthed in front of shares graph
    Share Market News

    Returning capital: These ASX companies have been buying back their shares in 2023

    Do you own any of these capital-returning shares?

    Read more »

    A young woman with her mouth open and her hands out showing surprise and delight as uranium share prices skyrocket
    Share Gainers

    Why CogState, Jumbo, Magellan, and St Barbara shares are rising today

    These ASX shares are having a positive session on Thursday.

    Read more »

    Rocket powering up and symbolising a rising share price.
    Earnings Results

    2 ASX All Ords stocks rocketing over 7% on strong results

    Guess which All Ords stock posted a 147% jump in profits last half.

    Read more »

    A worried man holds his head and look at his computer.
    Share Fallers

    Why Clinuvel, Cogstate, Omni Bridgeway, and Westgold shares are sinking

    These ASX shares are ending the week in a disappointing fashion...

    Read more »

    A man holds his head in his hands, despairing at the bad result he's reading on his computer.
    Earnings Results

    3 ASX All Ord shares being hammered on earnings today

    Investors have responded very negatively to these companies' results...

    Read more »

    a woman holds her hands to her temples as she sits in front of a computer screen with a concerned look on her face.
    Share Fallers

    Why A2 Milk, Altium, Cogstate, and Ingenia shares are sinking today

    Investors have been hitting the sell button on these shares on Tuesday...

    Read more »

    ASX shares downgrade A young woman with tattoos puts both thumbs down and scrunches her face with the bad news.
    Share Fallers

    Why CogState, Downer, Temple & Webster, and Woodside shares are dropping

    These ASX shares are dropping on Thursday...

    Read more »

    Small girl giving a fist bump with a piggy bank in front of her.
    Opinions

    These 2 small-cap ASX shares have soared, but a fund manager still tips them as buys

    Here are two picks in the WAM Microcap portfolio.

    Read more »

    a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
    Healthcare Shares

    2 ASX healthcare shares to buy that you've not heard of: expert

    If you want to invest in a sector that people still need during economic downturns, here's a pair of small…

    Read more »

    A young woman with glasses holds a pencil to her lips as she is surrounded by the reflection of data as though she is being photographed through a glass screen project with digital data.
    Technology Shares

    Here's how ASX tech shares fared in September

    It was mostly a sea of red for ASX tech shares in September...

    Read more »

    A women cheers with clenched fists having read some good news on her laptop.
    Share Gainers

    These were the 5 best-performing ASX All Ords shares in September

    These All Ords shares bucked the market weakness to shoot the lights out in September.

    Read more »

    Man drawing an upward line on a bar graph symbolising a rising share price.
    Share Gainers

    Why Cogstate, Global Lithium, Premier, and Woodside shares are charging higher

    These ASX shares are storming higher today...

    Read more »

    Frequently Asked Questions

    No, Cogstate does not pay dividends at this stage.

    Cogstate Ltd listed on the ASX on 13 February 2004.

    CGS ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Cogstate Ltd

    Cogstate Ltd (ASX: CGS) is a neuroscience technology company specialising in brain health assessments. The principal activity of the company is the sale of technology and services to measure cognition.

    The company provides licensed digital tests for health professionals and medical researchers. Its services include scientific consultancy, project management, data management, statistical analysis, and reporting. Cogstate generates the bulk of its revenue from its clinical trials segment. 

    Cogstate's technology has been used in more than 2,000 scientific and clinical trial studies. These include fields such as Alzheimer's, depression, and bipolar disorder research as well as studies investigating cognitive impairment in athletes as a result of concussive injuries.

    CGS Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    11 Jun 2024 $1.17 $0.02 1.74% 158,279 $1.11 $1.18 $1.11
    07 Jun 2024 $1.15 $-0.02 -1.71% 49,293 $1.15 $1.19 $1.14
    06 Jun 2024 $1.17 $-0.07 -5.65% 52,918 $1.21 $1.21 $1.15
    05 Jun 2024 $1.24 $0.09 7.83% 72,266 $1.17 $1.24 $1.15
    04 Jun 2024 $1.15 $-0.05 -4.17% 265,036 $1.20 $1.20 $1.11
    03 Jun 2024 $1.20 $-0.04 -3.23% 45,121 $1.20 $1.24 $1.19
    31 May 2024 $1.24 $0.14 12.73% 75,272 $1.10 $1.24 $1.09
    30 May 2024 $1.10 $-0.13 -10.57% 179,673 $1.23 $1.23 $1.10
    28 May 2024 $1.23 $-0.02 -1.60% 66,985 $1.24 $1.24 $1.23
    27 May 2024 $1.25 $0.01 0.81% 10,943 $1.27 $1.27 $1.24
    24 May 2024 $1.24 $-0.01 -0.80% 134,321 $1.18 $1.24 $1.18
    23 May 2024 $1.25 $0.00 0.00% 99,400 $1.25 $1.25 $1.23
    22 May 2024 $1.25 $-0.10 -7.41% 203,933 $1.25 $1.29 $1.22
    21 May 2024 $1.35 $0.06 4.63% 8,676 $1.30 $1.35 $1.30
    20 May 2024 $1.30 $0.00 0.00% 47,351 $1.28 $1.33 $1.28
    17 May 2024 $1.29 $0.04 3.20% 9,555 $1.26 $1.29 $1.26
    16 May 2024 $1.25 $-0.04 -3.10% 19,862 $1.29 $1.30 $1.24
    15 May 2024 $1.29 $0.04 3.20% 32,074 $1.20 $1.30 $1.16
    14 May 2024 $1.25 $0.01 0.81% 20,417 $1.23 $1.25 $1.20

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Martyn Kenneth Myer Non-Executive ChairmanNon-Executive Director Oct 1999
    Mr Myer is Chair of the Doherty Institute at the University of Melbourne and the boards of the Australian Chamber Orchestra and Watertrust Australia Limited. He previously served as Deputy Chancellor of the Council of the University of Melbourne, President of The Myer Foundation, one of two principle Myer Family philanthropic funds, President of the Howard Florey Institute of Experimental Physiology and Medicine and was a director of The Florey Institute of Neuroscience and Mental Health, where he participated in the transition of the Institute's research focus towards diagnostic and therapeutic neuroscience, including a focus on degenerative brain diseases. He is also a member of Risk and Compliance Committee.
    Mr Bradley O'Connor Chief Executive OfficerManaging Director Nov 2005
    Mr O'Connor has responsibility for Cogstate's overall strategic direction and day-to-day operations as well as development of expansion opportunities outside of the core clinical trials business. Prior to taking the position of CEO at Cogstate in 2005, Mr O'Connor joined Cogstate as Chief Financial Officer and Company Secretary in 2004. Prior to that, Mr O'Connor held senior positions at Spherion Group, Australian Wine Exchange and PricewaterhouseCoopers.
    Ms Ingrid Anne Player Non-Executive Director Aug 2019
    Ms Player brings healthcare sector experience and commercial expertise to the Board of Cogstate. She has held senior executive roles with Healthscope Ltd, a private healthcare provider in Australia, including the former positions of Group Executive Legal, Governance and Sustainability, and General Counsel and Company Secretary from 2005 until 2019. Ms Player also has international commercial and regulatory experience that spans different markets and industries, which she gained in private legal practice in Australia and in The Netherlands. She is Chair of Risk and Compliance Committee.
    Mr Richard van den Broek Non-Executive Director Aug 2010
    Mr van den Broek is founder and managing partner of HSMR Advisors LLC, a U.S. based fund manager with an investment emphasis on small and mid-cap biotech public companies. Prior to his time as an investor in the healthcare industry Mr van den Broek had a ten-year career as a biotech analyst, starting at Oppenheimer and Co., then Merrill Lynch, and finally at Hambrecht and Quist.
    Dr Richard Mohs Non-Executive Director Jan 2017
    Dr Mohs is currently Chief Scientific Officer for the Global Alzheimer's Platform (GAP) Foundation, a non-profit devoted to enhancing the speed and quality of Alzheimer's disease research. Richard also serves as a consultant to academic institutions, foundations, and biopharmaceutical companies, and is a member of the Board of Governors for the Alzheimer's Drug Discovery Foundation. Dr Mohs retired from Eli Lilly in 2015, where he held leadership positions including Vice President for Neuroscience Early Clinical Development and Leader of the Global Alzheimer's Drug Development Team. Before joining Eli Lilly, Dr Mohs spent 23 years with the Mount Sinai School of Medicine where he was Professor in the Department of Psychiatry and Associate Chief of Staff for Research at the Bronx Veterans Affairs Medical Centre. He is also a member of the Risk and Compliance Committee.
    Ms Kim Wenn Non-Executive Director Nov 2020
    Ms Wenn brings technology experience and commercial expertise to the Board of Cogstate, with over 30 years of experience in innovation roles. Until July 2018, Kim held the role of Chief Information Officer at Tabcorp Holdings, an ASX50 listed company where Kim led a team of 1,200 technology experts to drive strategic direction through digital transformation. Kim's experience includes, among other things, business strategy, governance, and change management with a focus on digital disruption. She is also a member of Risk and Compliance Committee.
    Mr David James Franks Company Secretary Feb 2021
    -
    Ms Kristi Geddes Joint Company Secretary Apr 2023
    -
    Darren Watson Chief Financial Officer
    -
    Paul Maruff Chief Innovation Officer
    -
    Chris Edgar Chief Science Officer
    -
    David James Franks Company Secretary
    -
    Rachel Colite Executive Vice President Clinical Trials
    -
    Kristi Geddes Joint Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Citicorp Nominees Pty Limited 26,467,388 15.30%
    Dagmar Dolby Fund 25,732,802 14.90%
    HSBC Custody Nominees 18,733,273 10.80%
    National Nominees Limited 18,423,798 10.60%
    Myer and Myer Pty Ltd 14,424,569 8.30%
    Anacacia Pty Limited 8,276,801 4.80%
    Mpyer Investments Pty Ltd 6,061,872 3.50%
    BNP Paribas Nominees Pty Ltd 5,796,914 3.30%
    Mr Bradley John O'Connor 3,488,429 2.00%
    BNP Paribas Noms Pty Ltd 2,919,932 1.80%
    HSBC Custody Nominees i 2,785,398 1.60%
    Myer and Myer Pty Ltd i 2,313,000 1.30%
    J P Morgan Nominees Australia 1,750,592 1.00%
    Mr Alistair David Strong 1,320,000 0.80%
    Mutual Trust Pty Ltd 1,223,806 0.70%
    Beta Gamma Pty Ltd 1,220,000 0.70%
    BNP Paribas Noms(Nz) Ltd<Drp> 1,209,851 0.70%
    BNP Paribas Nominees Pty Ltd i 1,169,901 0.70%
    Mr David Alexander Simpson 1,000,689 0.60%
    HSBC Custody Nominees ii 924,111 0.50%

    Profile

    since

    Note